Log in
OTCMKTS:ALPMY

ASTELLAS PHARMA/ADR Stock Forecast, Price & News

$15.31
-0.06 (-0.39 %)
(As of 09/25/2020 03:53 PM ET)
Add
Compare
Today's Range
$15.23
Now: $15.31
$15.35
50-Day Range
$15.04
MA: $15.68
$16.52
52-Week Range
$12.48
Now: $15.31
$18.43
Volume52,867 shs
Average Volume82,998 shs
Market Capitalization$28.50 billion
P/E Ratio15.95
Dividend Yield1.76%
Beta0.7
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents; and a research collaboration with NapaJen Pharma, Inc. for the discovery and development of oligonucleotide therapeutics. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Read More
ASTELLAS PHARMA/ADR logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
CUSIPN/A
CIKN/A
Phone813-3244-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.97 billion
Cash Flow$1.27 per share
Book Value$6.28 per share

Profitability

Miscellaneous

Employees15,883
Outstanding Shares1,861,787,000
Market Cap$28.50 billion
Next Earnings DateN/A
OptionableNot Optionable
$15.31
-0.06 (-0.39 %)
(As of 09/25/2020 03:53 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions

How has ASTELLAS PHARMA/ADR's stock price been impacted by COVID-19 (Coronavirus)?

ASTELLAS PHARMA/ADR's stock was trading at $15.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALPMY stock has decreased by 2.6% and is now trading at $15.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ASTELLAS PHARMA/ADR?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ASTELLAS PHARMA/ADR
.

How were ASTELLAS PHARMA/ADR's earnings last quarter?

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) posted its quarterly earnings data on Tuesday, August, 4th. The company reported $0.25 earnings per share for the quarter. The business had revenue of $2.85 billion for the quarter.
View ASTELLAS PHARMA/ADR's earnings history
.

When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work?

ASTELLAS PHARMA/ADR's stock split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split.

Are investors shorting ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 4,400 shares, a decrease of 91.3% from the August 31st total of 50,800 shares. Based on an average trading volume of 100,800 shares, the short-interest ratio is presently 0.0 days.
View ASTELLAS PHARMA/ADR's Short Interest
.

Who are some of ASTELLAS PHARMA/ADR's key competitors?

Who are ASTELLAS PHARMA/ADR's key executives?

ASTELLAS PHARMA/ADR's management team includes the following people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 59)
  • Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Linda Friedman, Gen. Counsel & VP
  • Dr. Sef P. Kurstjens, Chief Medical Officer and Pres of Global Devel. (Age 56)

What is ASTELLAS PHARMA/ADR's stock symbol?

ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of ASTELLAS PHARMA/ADR?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ASTELLAS PHARMA/ADR's stock price today?

One share of ALPMY stock can currently be purchased for approximately $15.31.

How big of a company is ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR has a market capitalization of $28.50 billion and generates $11.97 billion in revenue each year. The company earns $1.80 billion in net income (profit) each year or $0.96 on an earnings per share basis. ASTELLAS PHARMA/ADR employs 15,883 workers across the globe.

What is ASTELLAS PHARMA/ADR's official website?

The official website for ASTELLAS PHARMA/ADR is www.astellas.com.

How can I contact ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.